Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 14Breast Neoplasms 12Multiple Myeloma 8Neoplasm Metastasis 5Pain 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Renal Insufficiency 1Pleural Effusion, Malignant 1Osteoporosis 1Osteonecrosis 1Osteolysis 1Neoplastic Cells, Circulating 1Lung Neoplasms 1Lung Metastases 1Carcinoma, Renal Cell 1Bone Neoplasms 1Bone Diseases, Metabolic 1

Interventions

Risedronic Acid 2Zoledronic Acid 1Kyphoplasty 1Cholecalciferol 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Bone Diseases, Metabolic × Zoledronic Acid × Clear all
NCT00063609 2017-09-13

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Novartis

Phase 4 Completed
200 enrolled
Genitourinary

Bone Diseases, Metabolic, Osteoporosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡